Metastasis: Adaptable integrins

p3 | doi:10.1038/nrc709

Angiogenesis: What's going on?

p4 | doi:10.1038/nrc713

P53 regulation: 3 out of 4 ain't bad

p5 | doi:10.1038/nrc715

Therapeutics: Taking a bite out of tumours

p6 | doi:10.1038/nrc708

Carcinogens: Fishing for trouble

p6 | doi:10.1038/nrc712

Genomic instability: Protecting the code

p7 | doi:10.1038/nrc707

Tumour suppressors: Unfold with BRCA1

p8 | doi:10.1038/nrc714

Leukaemia: Gene expression 1, histology 0

p8 | doi:10.1038/nrc716

Therapeutic targets: From microarray to mechanism

p9 | doi:10.1038/nrc717

Scaling down imaging: molecular mapping of cancer in mice

Ralph Weissleder

p11 | doi:10.1038/nrc701

• Abstract
• Full Text
• PDF (368 KB)

The promise and peril of surrogate end points in cancer research

Arthur Schatzkin & Mitchell Gail

p19 | doi:10.1038/nrc702

• Abstract
• Full Text
• PDF (263 KB)

Helicobacter pylori and gastrointestinal tract adenocarcinomas

Richard M. Peek, Jr & Martin J. Blaser

p28 | doi:10.1038/nrc703

• Abstract
• Full Text
• PDF (691 KB)

Hypoxia — a key regulatory factor in tumour growth

Adrian L. Harris

p38 | doi:10.1038/nrc704

• Abstract
• Full Text
• PDF (1,001 KB)
• Supplementary information

Multidrug resistance in cancer: role of ATP–dependent transporters

Michael M. Gottesman, Tito Fojo & Susan E. Bates

p48 | doi:10.1038/nrc706

• Abstract
• Full Text
• PDF (536 KB)